Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.33 |
| ▸ | FEN1 | P39748 | 4/20 | 0.33 |
| ▸ | MAOB | P27338 | 4/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12823837 | 0.95 | FFAR4 (0.35) | F10NR1H4FFAR4ALOX5APFEN1 | |
| SCHEMBL12823001 | 0.89 | F10 (0.35) | F10NR1H4FFAR1FFAR4ALOX5AP | |
| SCHEMBL12822845 | 0.86 | F10 (0.36) | F10NR1H4FFAR1FFAR4ALOX5AP | |
| SCHEMBL13586391 | 0.86 | FFAR1 (0.38) | F10NR1H4FFAR1FFAR4ALOX5AP | |
| SCHEMBL13586288 | 0.86 | FEN1 (0.34) | ALOX5APFEN1 | |
| SCHEMBL13586126 | 0.86 | FEN1 (0.34) | ALOX5APFEN1 | |
| SCHEMBL12822464 | 0.86 | BRD4 (0.35) | BRD4 | |
| SCHEMBL12740867 | 0.86 | FFAR1 (0.39) | F10FFAR1 | |
| SCHEMBL13586394 | 0.85 | FFAR1 (0.41) | F10NR1H4FFAR1FFAR4ALOX5AP | |
| SCHEMBL12822757 | 0.85 | F10 (0.35) | F10NR1H4FFAR1FFAR4ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150966-A1 | TETRACYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | F10 950/4885NR1H4 1534/4885FFAR1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.